Glenmede Trust CO Na Bristol Myers Squibb CO Transaction History

Glenmede Trust CO Na

$19.6 Billion
Q2 2024

A detailed history of Glenmede Trust CO Na transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Glenmede Trust CO Na holds 1,239,711 shares of BMY stock, worth $65.9 Million. This represents 0.26% of its overall portfolio holdings.

Number of Shares

1,239,711

Previous 1,372,775 9.69%

Holding current value

$65.9 Million

Previous $74.4 Million 30.84%

% of portfolio

0.26%

Previous 0.38%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$40.25 - $52.99 $5.36 Million - $7.05 Million	-133,064 Reduced 9.69%	1,239,711 $51.5 Million
Q1 2024 May 15, 2024	SELL	$47.98 - $54.4 $1.7 Million - $1.93 Million	-35,413 Reduced 2.51%	1,372,775 $74.4 Million
Q4 2023 Feb 13, 2024	BUY	$48.48 - $57.85 $7.96 Million - $9.5 Million	164,182 Added 13.2%	1,408,188 $72.3 Million
Q3 2023 Nov 14, 2023	SELL	$57.89 - $64.73 $21 Million - $23.5 Million	-362,524 Reduced 22.57%	1,244,006 $72.2 Million
Q2 2023 Aug 14, 2023	SELL	$63.71 - $70.74 $28,542 - $31,691	-448 Reduced 0.03%	1,606,530 $103 Million
Q1 2023 May 15, 2023	BUY	$65.71 - $74.53 $711,245 - $806,712	10,824 Added 0.68%	1,606,978 $111 Million
Q4 2022 Feb 14, 2023	SELL	$68.48 - $81.09 $1.11 Million - $1.31 Million	-16,143 Reduced 1.0%	1,596,154 $115 Million
Q3 2022 Nov 16, 2022	BUY	$0.13 - $76.84 $1,102 - $651,449	8,478 Added 0.53%	1,612,297 $115 Million
Q2 2022 Aug 15, 2022	BUY	$72.62 - $79.98 $12.3 Million - $13.5 Million	169,230 Added 11.8%	1,603,819 $123 Million
Q1 2022 May 16, 2022	SELL	$61.48 - $73.72 $248,317 - $297,755	-4,039 Reduced 0.28%	1,434,589 $105 Million
Q4 2021 Feb 15, 2022	SELL	$53.63 - $62.52 $2.97 Million - $3.46 Million	-55,311 Reduced 3.7%	1,438,628 $89.7 Million
Q3 2021 Nov 15, 2021	SELL	$59.17 - $69.31 $958,258 - $1.12 Million	-16,195 Reduced 1.07%	1,493,939 $88.4 Million
Q2 2021 Aug 16, 2021	SELL	$61.91 - $67.42 $4.18 Million - $4.55 Million	-67,515 Reduced 4.28%	1,510,134 $101 Million
Q1 2021 May 18, 2021	SELL	$59.34 - $66.74 $4.3 Million - $4.84 Million	-72,528 Reduced 4.4%	1,577,649 $99.6 Million
Q4 2020 Feb 16, 2021	SELL	$57.74 - $65.43 $118,078 - $133,804	-2,045 Reduced 0.12%	1,650,177 $102 Million
Q3 2020 Nov 16, 2020	SELL	$57.43 - $63.64 $549,317 - $608,716	-9,565 Reduced 0.58%	1,652,222 $99.6 Million
Q2 2020 Aug 14, 2020	SELL	$54.82 - $64.09 $100 Million - $117 Million	-1,825,581 Reduced 52.35%	1,661,787 $97.7 Million
Q4 2019 Feb 12, 2020	BUY	$49.21 - $64.19 $76.8 Million - $100 Million	1,560,071 Added 80.95%	3,487,368 $224 Million
Q3 2019 Nov 14, 2019	BUY	$42.77 - $50.71 $9.32 Million - $11 Million	217,842 Added 12.74%	1,927,297 $97.7 Million
Q2 2019 Aug 13, 2019	BUY	$44.62 - $49.34 $12.4 Million - $13.8 Million	278,728 Added 19.48%	1,709,455 $77.5 Million
Q1 2019 May 14, 2019	BUY	$45.12 - $53.8 $35 Million - $41.7 Million	775,266 Added 118.28%	1,430,727 $68.3 Million
Q4 2018 Feb 14, 2019	BUY	$48.76 - $63.23 $4.53 Million - $5.87 Million	92,873 Added 16.51%	655,461 $34.1 Million
Q3 2018 Nov 15, 2018	BUY	$55.19 - $62.25 $5.43 Million - $6.13 Million	98,436 Added 21.21%	562,588 $34.9 Million
Q2 2018 Nov 05, 2018	SELL	$50.53 - $62.98 $46.2 Million - $57.6 Million	-913,952 Reduced 66.32%	464,152 $25.7 Million
Q2 2018 Aug 15, 2018	BUY	$50.53 - $62.98 $47.1 Million - $58.7 Million	932,381 Added 209.18%	1,378,104 $76.3 Million
Q4 2017 Feb 15, 2018	BUY	$59.94 - $65.35 $2.67 Million - $2.91 Million	44,579 Added 11.11%	445,723 $27.3 Million
Q3 2017 Nov 14, 2017	BUY	$55.23 - $63.74 $22.2 Million - $25.6 Million	401,144	401,144 $0

Others Institutions Holding BMY

# of Institutions

2,428

Shares Held

1.5B

Call Options Held

29.7M

Put Options Held

32.2M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

News

Stay updated on Glenmede Trust CO Na with notifications on news.

Account

Glenmede Trust CO Na Bristol Myers Squibb CO Transaction History